Decipher GRID Study Identifies Prostate Cancer Biomarkers

Decipher GRID Study Identifies Prostate Cancer Biomarkers
GenomeDx Biosciences has recently announced the publication of a new study titled "Characterization of 1,577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes"  utilizing Decipher GRID technology. Decipher GRID is a genomics database that can be used to identify subtypes of prostate cancer. The assay identifies prostate cancer biomarkers, including ERG, a biomarker that indicates whether a patient could be resistant to certain treatments. The study, which appeared in the journal European Urology, analyzed a total of 1,577 low, intermediate and high risk patients from several countries, who donated tumor tissue for the investigation. Decipher GRID identified prostate cancer subtypes and was able to identify ERG with 95% accuracy when compared to FISH (Florescent in situ hybridization), a commonly used method. The researchers looked at several other prostate cancer biomarkers including ETV1, ETV4, ETV5, FLI1 and SPINK1, all of which could be identified by Decipher GRID. "The findings from this study are important since we know that men with prostate cancer harbor multiple genetically independent tumor clones that may have variable morphology such as Gleason score," noted Scott A. Tomlins M.D., Ph.D., Assistant Professor of Urology and Pathology, University of Michigan Medical School. "That means we may be able to use this technology to
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *